Biotech News

Coherus Oncology Retains Oppenheimer & Co. to Market Legacy BioSimilar Assets

Coherus BioSciences, Inc. (CHRS)Coherus BioSciences, Inc.2026-09-23 13:30 ESTCompany update

- Oppenheimer Initiates a Robust Process with Global Reach for the Benefit of Shareholders - REDWOOD CITY, Calif., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS) today announced that it has initiated the process to market and sell the remaining assets associated with the

Related news

CHRSCoherus BioSciences, Inc.2026-08-17 21:33 EST

Coherus Oncology Announces Special Dividend of Biosimilar Contingent Value Rights

CHRSCoherus BioSciences, Inc.2026-08-31 13:30 EST

Coherus to Participate in Upcoming Investor Conferences

ALVOAlvotech2026-08-31 08:30 EST

Alvotech announces FDA acceptance for review of Biologics License Application for AVT80, expanding proposed biosimilar program for Entyvio® to subcutaneous presentations

NRIXNurix Therapeutics2026-10-05 11:00 EST

Nurix Therapeutics Announces Second Research Term Extension for Oncology Program Under Collaboration with Gilead Sciences

KURAKura Oncology2026-10-02 11:30 EST

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

KURAKura Oncology2026-09-08 11:00 EST

Kura Oncology Appoints Jennifer Fulk as Chief Financial Officer

ELVNEnliven Therapeutics2026-08-31 22:05 EST

Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting

View all latest news

Coherus BioSciences, Inc.

Immuno-Oncology Portfolio Coherus Oncology develops antibody-based cancer therapies intended to overcome immune suppression in the tumor microenvironment. Its pipeline combines internally controlled candidates with toripalimab, marketed in the United States as LOQTORZI. Casdozokitug Casdozokitug is an anti-IL-27 antibody being studied...

Recent company news

CHRSCoherus BioSciences, Inc.2026-09-23 13:30 EST

Coherus Oncology Retains Oppenheimer & Co. to Market Legacy BioSimilar Assets

CHRSCoherus BioSciences, Inc.2026-08-31 13:30 EST

Coherus to Participate in Upcoming Investor Conferences

CHRSCoherus BioSciences, Inc.2026-08-17 21:33 EST

Coherus Oncology Announces Special Dividend of Biosimilar Contingent Value Rights

CHRSCoherus BioSciences, Inc.2026-08-05 20:28 EST

Coherus Oncology Reports Second Quarter 2026 Financial Results and Provides Business Update

CHRSCoherus BioSciences, Inc.2026-07-22 17:36 EST

Coherus Oncology to Report Second Quarter 2026 Financial Results on August 5, 2026

Stock data

Close: 1.16 USD
Market cap: 234.46M USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States